Denali Therapeutics (DNLI) Insider Trading & Ownership $25.05 -3.40 (-11.95%) (As of 11/15/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Denali Therapeutics (NASDAQ:DNLI) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage7.90%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$6.31 M Get DNLI Insider Trade Alerts Want to know when executives and insiders are buying or selling Denali Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address DNLI Insider Buying and Selling by Quarter Ad WealthPressHow one pattern has averaged an 85% return per year since the pandemic. Over the last 5 years Roger Scott has done some pretty incredible things… He’s found hundreds of winning opportunities… He’s created some incredible strategies… And he’s even designed some amazing tools… But there is one thing he’s always kept close to the chest… And in this case, it’s been a very particular stock market pattern…. A pattern he calls the World's Most Predictable Pattern…Follow this link here and enter your email address to sign up… Denali Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/7/2024Alexander O SchuthInsiderSell15,558$29.91$465,339.78 11/7/2024Vicki L SatoDirectorSell1,020$30.00$30,600.00 10/18/2024Ryan J WattsCEOSell40,000$27.69$1,107,600.00 9/30/2024Steve E KrognesDirectorSell30,000$29.03$870,900.00 7/1/2024Steve E KrognesDirectorSell30,000$22.12$663,600.00 6/13/2024Steve E KrognesDirectorSell688$21.79$14,991.52 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 6/6/2024Jennifer E CookDirectorSell1,458$21.73$31,682.34 4/15/2024Vicki L SatoDirectorSell1,666$18.29$30,471.14 4/1/2024Steve E KrognesDirectorSell92,500$20.50$1,896,250.00 2/15/2024Vicki L SatoDirectorSell1,666$18.37$30,604.42 2/13/2024Carole HoInsiderSell2,784$17.29$48,135.36 2/13/2024Ryan J WattsCEOSell9,589$17.29$165,793.81 2/13/2024Steve E KrognesDirectorSell2,750$17.29$47,547.50 1/16/2024Vicki L SatoDirectorSell1,666$18.42$30,687.72 1/10/2024Carole HoInsiderSell4,668$19.02$88,785.36 1/9/2024Ryan J WattsCEOSell7,818$19.78$154,640.04 1/5/2024Carole HoInsiderSell9,972$19.43$193,755.96 1/5/2024Ryan J WattsCEOSell17,483$19.43$339,694.69 1/5/2024Steve E KrognesDirectorSell3,208$19.43$62,331.44 12/15/2023Vicki L SatoDirectorSell1,666$23.39$38,967.74 (Data available from 1/1/2013 forward) DNLI Insider Trading Activity - Frequently Asked Questions Who is on Denali Therapeutics's Insider Roster? The list of insiders at Denali Therapeutics includes Alexander O Schuth, Carole Ho, Jennifer E Cook, Marc Tessier-Lavigne, Ryan J Watts, Steve E Krognes, and Vicki L Sato. Learn more on insiders at DNLI. What percentage of Denali Therapeutics stock is owned by insiders? 7.90% of Denali Therapeutics stock is owned by insiders. Learn more on DNLI's insider holdings. Which Denali Therapeutics insiders have been selling company stock? The following insiders have sold DNLI shares in the last 24 months: Alexander O Schuth ($1,470,393.86), Carole Ho ($950,856.53), Jennifer E Cook ($31,682.34), Marc Tessier-Lavigne ($609,600.00), Ryan J Watts ($3,829,413.31), Steve E Krognes ($3,810,529.72), and Vicki L Sato ($406,482.92). How much insider selling is happening at Denali Therapeutics? Insiders have sold a total of 445,563 Denali Therapeutics shares in the last 24 months for a total of $11,108,958.68 sold. Denali Therapeutics Key ExecutivesDr. Ryan J. Watts Ph.D. (Age 48)Co-Founder, President, CEO & Director Compensation: $1.15MDr. Alexander O. Schuth M.D. (Age 51)Co-Founder, CFO, COO & Secretary Compensation: $802.29k1 recent tradesDr. Marc Tessier-Lavigne Ph.D. (Age 64)Co-Founder & Independent Director Compensation: $57.5kDr. Carole Ho M.D. (Age 51)Chief Medical Officer & Head of Development Compensation: $802.29kMr. Tyler M. Nielsen (Age 46)Senior Vice President of Corporate Finance Dr. Dana AndersenChief Technical and Manufacturing OfficerMr. Joe Lewcock Ph.D.Chief Scientific OfficerDr. Laura HansenVice President of Investor RelationsMr. Chris WalshGeneral CounselMr. Mark RowenVice President of Corporate Development More Insider Trading Tools from MarketBeat Related Companies CYTK Insider Ownership PRTA Insider Ownership RGNX Insider Ownership BMRN Insider Ownership PCVX Insider Ownership NBIX Insider Ownership TECH Insider Ownership EXEL Insider Ownership RVMD Insider Ownership RGEN Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:DNLI) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
